{"title":"增加了局部晚期头颈部鳞状细胞癌症放化疗中每周一次与每三周一次顺铂给药的争论","authors":"V. Noronha, V. Patil, A. Joshi, K. Prabhash","doi":"10.21037/tro.2018.12.04","DOIUrl":null,"url":null,"abstract":"One of the most popular debates in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is the optimal dose and schedule of cisplatin when combined with radical radiotherapy in the curative setting, both postoperatively and as definitive chemoradiotherapy (CRT). Hoping to settle this debate once and for all, we conducted a phase III randomized clinical trial to answer this question (1).","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer\",\"authors\":\"V. Noronha, V. Patil, A. Joshi, K. Prabhash\",\"doi\":\"10.21037/tro.2018.12.04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"One of the most popular debates in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is the optimal dose and schedule of cisplatin when combined with radical radiotherapy in the curative setting, both postoperatively and as definitive chemoradiotherapy (CRT). Hoping to settle this debate once and for all, we conducted a phase III randomized clinical trial to answer this question (1).\",\"PeriodicalId\":93236,\"journal\":{\"name\":\"Therapeutic radiology and oncology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic radiology and oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/tro.2018.12.04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic radiology and oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/tro.2018.12.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer
One of the most popular debates in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is the optimal dose and schedule of cisplatin when combined with radical radiotherapy in the curative setting, both postoperatively and as definitive chemoradiotherapy (CRT). Hoping to settle this debate once and for all, we conducted a phase III randomized clinical trial to answer this question (1).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
